Hebei Weimiao Biology Co., LTD 1
Location
  • Home
  • china bicalutamide cas 90357-06-5

Dec . 18, 2024 01:54 Back to list

china bicalutamide cas 90357-06-5



Understanding Bicalutamide A Comprehensive Overview


Bicalutamide, with the Chemical Abstracts Service (CAS) number 90357-06-5, is an anti-androgen medication widely utilized in the treatment of prostate cancer. As a non-steroidal compound, it works primarily by inhibiting the action of androgens, such as testosterone, at the cellular level. This mechanism of action has made it a vital component in the therapeutic landscape for prostate cancer, especially in cases where hormone therapy is deemed necessary.


Mechanism of Action


Bicalutamide functions as a selective antagonist of androgen receptors. By binding to these receptors, it prevents testosterone and other androgenic hormones from exerting their effects on prostate cancer cells. This is crucial because many of these cancers thrive on androgens for growth and proliferation. By blocking this pathway, bicalutamide can slow down or even regress tumor growth, providing significant benefits to patients.


The drug is typically administered in conjunction with other treatments, such as luteinizing hormone-releasing hormone (LHRH) agonists or surgical castration, to achieve maximum efficacy in reducing androgen levels and blocking their effects on tumors. The result is a multi-faceted approach to combating prostate cancer, which is characterized by its complex nature and varying responses to treatment.


Clinical Applications

Initially approved for use in advanced prostate cancer, bicalutamide has also gained attention for its use in treating other hormone-sensitive conditions. The most common indication remains in combination therapy for metastatic prostate cancer, where it plays a pivotal role in hormone blockade. Furthermore, studies have been conducted to explore its potential in managing benign prostatic hyperplasia (BPH) and specific cases of female hirsutism, though these applications are less established.


Side Effects and Considerations


china bicalutamide cas 90357-06-5

<trp-post-container data-trp-post-id='18041'>china bicalutamide cas 90357-06-5</trp-post-container>

Like all medications, bicalutamide is associated with a range of side effects. Commonly reported issues include hot flashes, gastrointestinal disturbances, fatigue, and breast tenderness or enlargement. In some cases, it can lead to more severe complications, such as liver toxicity, which necessitates careful monitoring of liver function during treatment.


Healthcare providers must weigh the benefits of bicalutamide against its potential risks, particularly in patients with pre-existing liver conditions or those on concurrent medications that may exacerbate hepatic issues. Regular follow-ups and adjustments to treatment protocols are crucial in ensuring patient safety and optimizing therapeutic outcomes.


Research and Future Directions


The ongoing research surrounding bicalutamide and its uses continues to evolve. Studies are exploring its efficacy in combination with novel agents and therapies, aiming to improve outcomes for patients with advanced or resistant forms of prostate cancer. Additionally, there is interest in its role in precision medicine, where genetic markers may help determine which patients are most likely to benefit from bicalutamide treatment.


Furthermore, the pharmacokinetics of bicalutamide are being examined to refine dosing strategies and minimize side effects, enhancing the overall quality of life for patients. Understanding the drug’s interactions with other medications, particularly in polypharmacy contexts, is another important area of study.


Conclusion


Bicalutamide, identified by its CAS number 90357-06-5, remains a cornerstone in the treatment of prostate cancer, exemplifying the importance of targeted therapy in oncology. Its unique mechanism of inhibiting androgen receptor activity provides an essential tool for clinicians aiming to manage this complex disease. As research continues to advance, bicalutamide's role in the treatment paradigm will likely evolve, potentially expanding its applications and improving treatment outcomes for patients facing hormone-sensitive malignancies.


Share
Next：

Latest news

If you are interested in our products, you can choose to leave your information here, and we will be in touch with you shortly.


Hit enter to search or ESC to close
sdSindhi
en_USEnglish afAfrikaans sqAlbanian amAmharic arArabic hyArmenian azAzerbaijani euBasque belBelarusian bn_BDBengali bs_BABosnian bg_BGBulgarian caCatalan cebCebuano zh_CNChina zh_TWChina (Taiwan) coCorsican hrCroatian cs_CZCzech da_DKDanish nl_NLDutch eoEsperanto etEstonian fiFinnish fr_FRFrench fyFrisian gl_ESGalician ka_GEGeorgian de_DEGerman elGreek guGujarati htHaitian Creole haHausa hawHawaiian he_ILHebrew hi_INHindi hmnMiao hu_HUHungarian is_ISIcelandic igIgbo id_IDIndonesian gaIrish it_ITItalian jaJapanese jvJavanese knKannada kkKazakh kmKhmer rwRwandese ko_KRKorean ckbKurdish kyKyrgyz loLao laLatin lvLatvian lt_LTLithuanian lbLuxembourgish mk_MKMacedonian mgMalgashi ms_MYMalay ml_INMalayalam mtMaltese miMaori mrMarathi mnMongolian my_MMMyanmar ne_NPNepali nb_NONorwegian nyNorwegian orOccitan psPashto fa_IRPersian pl_PLPolish pt_PTPortuguese pa_INPunjabi ro_RORomanian ru_RURussian smSamoan gdScottish Gaelic sr_RSSerbian stSesotho snShona si_LKSinhala sk_SKSlovak sl_SISlovenian soSomali es_ESSpanish suSundanese swSwahili sv_SESwedish tlTagalog tgTajik ta_INTamil tt_RUTatar teTelugu thThai tr_TRTurkish tkTurkmen ukUkrainian urUrdu ug_CNUighur uz_UZUzbek viVietnamese cyWelsh xhBantu yiYiddish yoYoruba zuZulu sdSindhi